JP2024530795A - ニロガセスタットの合成 - Google Patents
ニロガセスタットの合成 Download PDFInfo
- Publication number
- JP2024530795A JP2024530795A JP2024514095A JP2024514095A JP2024530795A JP 2024530795 A JP2024530795 A JP 2024530795A JP 2024514095 A JP2024514095 A JP 2024514095A JP 2024514095 A JP2024514095 A JP 2024514095A JP 2024530795 A JP2024530795 A JP 2024530795A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharma
- acceptable salt
- ceutically acceptable
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/04—Formation of amino groups in compounds containing carboxyl groups
- C07C227/06—Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid
- C07C227/08—Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid by reaction of ammonia or amines with acids containing functional groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/26—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing carboxyl groups by reaction with HCN, or a salt thereof, and amines, or from aminonitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/44—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Health & Medical Sciences (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163239696P | 2021-09-01 | 2021-09-01 | |
| US63/239,696 | 2021-09-01 | ||
| PCT/US2022/075839 WO2023034917A1 (en) | 2021-09-01 | 2022-09-01 | Synthesis of nirogacestat |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024530795A true JP2024530795A (ja) | 2024-08-23 |
| JP2024530795A5 JP2024530795A5 (https=) | 2025-09-10 |
Family
ID=85413129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024514095A Pending JP2024530795A (ja) | 2021-09-01 | 2022-09-01 | ニロガセスタットの合成 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US12110277B2 (https=) |
| EP (1) | EP4396159A4 (https=) |
| JP (1) | JP2024530795A (https=) |
| KR (1) | KR20240056726A (https=) |
| CN (1) | CN118043305A (https=) |
| AR (1) | AR126961A1 (https=) |
| AU (1) | AU2022339841A1 (https=) |
| CA (1) | CA3230245A1 (https=) |
| CL (2) | CL2024000608A1 (https=) |
| CO (1) | CO2024002573A2 (https=) |
| IL (1) | IL311128A (https=) |
| MX (1) | MX2024002590A (https=) |
| PE (1) | PE20241348A1 (https=) |
| TW (1) | TWI905452B (https=) |
| WO (1) | WO2023034917A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022339841A1 (en) | 2021-09-01 | 2024-03-28 | Springworks Therapeutics, Inc. | Synthesis of nirogacestat |
| US11504354B1 (en) | 2021-09-08 | 2022-11-22 | SpringWorks Therapeutics Inc.. | Chlorinated tetralin compounds and pharmaceutical compositions |
| CN119930523B (zh) * | 2025-01-22 | 2026-01-02 | 上海皓元医药股份有限公司 | 一种硝加司他中间体的制备方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO5160260A1 (es) | 1999-02-19 | 2002-05-30 | Lilly Co Eli | Secretagogos de la hormona del crecimiento derivados de imi- dazol 1,4- substituido |
| GT200100147A (es) | 2000-07-31 | 2002-06-25 | Derivados de imidazol | |
| CA2533554A1 (en) | 2003-08-01 | 2005-02-10 | Pfizer Products Inc. | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders |
| DK1730119T3 (da) | 2004-03-23 | 2008-08-11 | Pfizer Prod Inc | Imidazolforbindelser til behandling af neurodegenerative forstyrrelser |
| US7232820B2 (en) | 2004-04-01 | 2007-06-19 | Pfizer Inc | Thiadiazole-amine compounds for the treatment of neurodegenerative disorders |
| AU2006293619A1 (en) * | 2005-09-22 | 2007-03-29 | Pfizer Products Inc. | Imidazole compounds for the treatment of neurological disorders |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| WO2015120065A1 (en) | 2014-02-05 | 2015-08-13 | The Trustees Of Columbia University In The City Of New York | Gamma-secretase inhibition reduce apoc3 levels and plasma triglycerides |
| BR112017013981A2 (pt) | 2015-01-26 | 2018-01-02 | Cellectis | receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer |
| US10294304B2 (en) | 2015-04-13 | 2019-05-21 | Pfizer Inc. | Chimeric antigen receptors targeting B-cell maturation antigen |
| RU2018101897A (ru) | 2015-06-22 | 2019-07-24 | Сумитомо Дайниппон Фарма Ко., Лтд. | Бициклическое гетероциклическое амидное производное |
| WO2017019496A1 (en) | 2015-07-24 | 2017-02-02 | Berenson James Richard | Gamma secretase modulators for the treatment of immune system dysfunction |
| US20190185559A1 (en) | 2016-09-02 | 2019-06-20 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating neoplasias |
| MX2019009552A (es) | 2017-02-17 | 2019-10-02 | Hutchinson Fred Cancer Res | Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios. |
| US20200179511A1 (en) | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| WO2019053727A1 (en) | 2017-09-18 | 2019-03-21 | Ramot At Tel-Aviv University Ltd. | REDIFFERENCING IN VITRO DEVELOPED CELLS FROM HUMAN PANCREATIC ISLAND BEA CELLS ADULPTED BY SMALL MOLECULE INHIBITORS OF THE SIGNALING PATH |
| PT3703750T (pt) | 2017-11-01 | 2025-01-17 | Memorial Sloan Kettering Cancer Center | Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes |
| MX2020004568A (es) | 2017-11-06 | 2020-10-05 | Juno Therapeutics Inc | Combinación de una terapia celular y un inhibidor de gamma secretasa. |
| KR102870868B1 (ko) | 2018-06-01 | 2025-10-15 | 노파르티스 아게 | Bcma에 대한 결합 분자 및 이의 용도 |
| EP3873937A2 (en) | 2018-11-01 | 2021-09-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d) |
| MA54078A (fr) | 2018-11-01 | 2021-09-15 | Juno Therapeutics Inc | Méthodes pour le traitement au moyen de récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b |
| CN113924318B (zh) | 2019-04-10 | 2025-06-20 | 葛兰素史密斯克莱知识产权发展有限公司 | 具有抗BCMA抗体和gamma分泌酶抑制剂的联合疗法 |
| PL4010322T3 (pl) | 2019-08-09 | 2026-02-16 | Pfizer Inc. | Stałe postacie (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaftalen-2-ylo)amino)-n-(1-(2-metylo-1-(neopentyloamino)propan-2-ylo)-1h-imidazol-4-ilo)pentanamidu i ich zastosowanie |
| US20230049311A1 (en) | 2019-08-09 | 2023-02-16 | Springworks Therapeutics, Inc. | Methods of treating desmoid tumors with (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide |
| KR102772889B1 (ko) | 2019-08-09 | 2025-02-26 | 화이자 인코포레이티드 | (s)-2-(((s)-6,8-디플루오로-1,2,3,4-테트라하이드로나프탈렌-2-일)아미노)-n-(1-(2-메틸-1-(네오펜틸아미노)프로판-2-일)-1h-이미다졸-4-일)펜탄아미드의 고체 상태 형태 및 이의 용도 |
| EP4090361A1 (en) | 2020-01-16 | 2022-11-23 | Allogene Therapeutics, Inc. | Combination therapies of chimeric antigen receptors targeting b-cell maturation antigen and gamma secretase inhibitors |
| BR112022018251A2 (pt) | 2020-03-13 | 2022-11-08 | Springworks Therapeutics Inc | Terapia de combinação com nirogacestat e terapia dirigida a bcma e usos da mesma |
| AU2022339841A1 (en) | 2021-09-01 | 2024-03-28 | Springworks Therapeutics, Inc. | Synthesis of nirogacestat |
| US11504354B1 (en) | 2021-09-08 | 2022-11-22 | SpringWorks Therapeutics Inc.. | Chlorinated tetralin compounds and pharmaceutical compositions |
-
2022
- 2022-09-01 AU AU2022339841A patent/AU2022339841A1/en active Pending
- 2022-09-01 WO PCT/US2022/075839 patent/WO2023034917A1/en not_active Ceased
- 2022-09-01 TW TW111133195A patent/TWI905452B/zh active
- 2022-09-01 JP JP2024514095A patent/JP2024530795A/ja active Pending
- 2022-09-01 US US17/929,153 patent/US12110277B2/en active Active
- 2022-09-01 EP EP22865803.5A patent/EP4396159A4/en active Pending
- 2022-09-01 CN CN202280066699.4A patent/CN118043305A/zh active Pending
- 2022-09-01 PE PE2024000346A patent/PE20241348A1/es unknown
- 2022-09-01 KR KR1020247009011A patent/KR20240056726A/ko active Pending
- 2022-09-01 AR ARP220102373A patent/AR126961A1/es unknown
- 2022-09-01 CA CA3230245A patent/CA3230245A1/en active Pending
- 2022-09-01 MX MX2024002590A patent/MX2024002590A/es unknown
- 2022-09-01 IL IL311128A patent/IL311128A/en unknown
- 2022-09-30 US US17/937,283 patent/US12247012B2/en active Active
-
2023
- 2023-04-20 US US18/304,202 patent/US12234210B2/en active Active
-
2024
- 2024-02-28 CL CL2024000608A patent/CL2024000608A1/es unknown
- 2024-02-29 CO CONC2024/0002573A patent/CO2024002573A2/es unknown
-
2025
- 2025-02-24 US US19/061,962 patent/US20250361212A1/en active Pending
- 2025-11-10 CL CL2025003464A patent/CL2025003464A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230091415A1 (en) | 2023-03-23 |
| US20230312480A1 (en) | 2023-10-05 |
| CL2024000608A1 (es) | 2024-10-04 |
| US20230089434A1 (en) | 2023-03-23 |
| WO2023034917A1 (en) | 2023-03-09 |
| US12247012B2 (en) | 2025-03-11 |
| US12234210B2 (en) | 2025-02-25 |
| AU2022339841A1 (en) | 2024-03-28 |
| EP4396159A4 (en) | 2026-04-15 |
| CA3230245A1 (en) | 2023-03-09 |
| CN118043305A (zh) | 2024-05-14 |
| US12110277B2 (en) | 2024-10-08 |
| TWI905452B (zh) | 2025-11-21 |
| PE20241348A1 (es) | 2024-07-03 |
| CO2024002573A2 (es) | 2024-03-07 |
| IL311128A (en) | 2024-04-01 |
| CL2025003464A1 (es) | 2026-02-27 |
| US20250361212A1 (en) | 2025-11-27 |
| AR126961A1 (es) | 2023-12-06 |
| MX2024002590A (es) | 2024-03-22 |
| EP4396159A1 (en) | 2024-07-10 |
| KR20240056726A (ko) | 2024-04-30 |
| TW202328068A (zh) | 2023-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024530795A (ja) | ニロガセスタットの合成 | |
| JP2020523381A (ja) | ３’−デオキシアデノシン−５’−ｏ−［フェニル（ベンジルオシキ−ｌ−アラニニル）］ホスフェート（ｎｕｃ−７７３８）の合成 | |
| TW201713669A (zh) | 合成雷帕黴素衍生物的方法 | |
| EP3845521B1 (en) | Synthesis methods for upadacitinib and intermediate thereof | |
| US20210292276A1 (en) | Polymorphic forms of belinostat and processes for preparation thereof | |
| WO2022204947A1 (zh) | 一种连接基药物偶联物的制备方法及其中间体 | |
| CN112272665B (zh) | 制备立他司特的方法 | |
| WO2002094816A1 (en) | Process for the crystallization of losartan potassium | |
| JP5787893B2 (ja) | ビフェニルイミダゾール化合物の調製方法 | |
| EP3512835A1 (en) | A process for purification of carfilzomib intermediate | |
| US20100249394A1 (en) | Processes for producing decitabine | |
| KR100900177B1 (ko) | 트리테르펜 유도체의 제조 방법 | |
| CN113816955B (zh) | 一种ret激酶抑制剂中间体及其制备方法 | |
| JP2019131532A (ja) | 酸無水物、および該酸無水物を用いたｌ−カルノシンの製造方法 | |
| CN117858866A (zh) | 用于制备色胺衍生物的方法 | |
| CN117677613A (zh) | 单环吡啶衍生物的合成中间体的制造方法 | |
| EP3848381A1 (en) | Method for producing glycoside compound | |
| EP0641783A1 (en) | Process for preparing 1,2-pyrazolidine-4-yl-disulfide compound | |
| CZ296780B6 (cs) | Zpusob prípravy amidu | |
| HK40003591B (en) | Polymorphic forms of belinostat and processes for preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250901 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250901 |